ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TSHA vs VOR // 10Y YIELD & FRED MACRO BETA

Taysha Gene Therapies Inc. (NASDAQ) VS. Vor Biopharma Inc. (NASDAQ) • 15-METRIC TALLY: TSHA 3 — VOR 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TSHA VS. VOR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TSHA VOR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -6.82% -11.61% +4.79 TSHA /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 17.30% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 5.67 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 TSHA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 43.8 50.6 -6.84 VOR /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.38B $1.24B $137.9M TSHA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TSHA REV VOR REV TSHA GROSS % VOR GROSS % TSHA FCF VOR FCF
FY 2025 $9.8M $0 — — -$93.8M -$143.7M
FY 2024 $8.3M $0 — — -$81.6M -$99.9M
FY 2023 $15.5M $0 — — -$73.0M -$100.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TSHA // BETA —
VOR // BETA —